# Post-Market Bioequivalence of Generic Drug Products

Canonical: https://abierto.us/opportunities/amendment75f40123r00023

- Solicitation number: Amendment75F40123R00023
- Notice type: Solicitation
- Status: Closed. Deadline was February 29, 2024 at 10:00 AM EST
- Department: Department of Health and Human Services
- Agency: Food and Drug Administration
- Contracting office: FDA Center for Drug Evaluation and Research (75DKKN)
- NAICS: 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Product or service code: B529 Scientific Data Studies
- First posted: February 9, 2024
- Last posted: February 21, 2024
- SAM.gov: https://sam.gov/workspace/contract/opp/a61cb6f8702d40b99ff72b3cef1de241/view

## Description

This posting serves as an amendment to Solicitation 75F40124R00023. Q&A were revised, see attached. Proposals are due 10EST 02/29/2024

## Publications

- February 9, 2024: Solicitation, due February 29, 2024 at 10:00 AM EST. Notice 94d6314ee2624b759e10ca2e7678a2f0. https://sam.gov/workspace/contract/opp/94d6314ee2624b759e10ca2e7678a2f0/view
- February 21, 2024: Solicitation, due February 29, 2024 at 10:00 AM EST. Notice a61cb6f8702d40b99ff72b3cef1de241. https://sam.gov/workspace/contract/opp/a61cb6f8702d40b99ff72b3cef1de241/view

## Points of contact

- Telisha WIlson, telisha.wilson@fda.hhs.gov

---
Source: SAM.gov Contract Opportunities bulk extract. Confirm deadlines on SAM.gov before responding. Cite https://abierto.us/opportunities/amendment75f40123r00023.